88.08
8.03%
6.645
Irhythm Technologies Inc stock is traded at $88.08, with a volume of 742.46K.
It is up +8.03% in the last 24 hours and up +40.29% over the past month.
iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio includes ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for several days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.
See More
Previous Close:
$81.44
Open:
$80.94
24h Volume:
742.46K
Relative Volume:
1.26
Market Cap:
$2.66B
Revenue:
$492.68M
Net Income/Loss:
$-123.41M
P/E Ratio:
-25.46
EPS:
-3.46
Net Cash Flow:
$-90.53M
1W Performance:
+14.26%
1M Performance:
+40.29%
6M Performance:
-14.32%
1Y Performance:
+5.64%
Irhythm Technologies Inc Stock (IRTC) Company Profile
Name
Irhythm Technologies Inc
Sector
Industry
Phone
415-632-5700
Address
699 8TH STREET, San Francisco, CA
Irhythm Technologies Inc Stock (IRTC) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-11-23 | Upgrade | Citigroup | Neutral → Buy |
Jul-19-23 | Initiated | Robert W. Baird | Outperform |
Feb-07-23 | Initiated | Wells Fargo | Overweight |
Nov-07-22 | Upgrade | Wolfe Research | Underperform → Peer Perform |
Jun-09-22 | Downgrade | Citigroup | Buy → Neutral |
Apr-06-22 | Initiated | Wolfe Research | Underperform |
Feb-24-22 | Upgrade | Needham | Hold → Buy |
Jan-18-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Jan-12-22 | Upgrade | BTIG Research | Neutral → Buy |
Jan-11-22 | Upgrade | Oppenheimer | Perform → Outperform |
Dec-21-21 | Resumed | Canaccord Genuity | Buy |
Dec-17-21 | Upgrade | JP Morgan | Neutral → Overweight |
Dec-15-21 | Upgrade | Citigroup | Neutral → Buy |
Jun-02-21 | Downgrade | Citigroup | Buy → Neutral |
Apr-13-21 | Downgrade | BTIG Research | Buy → Neutral |
Apr-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
Feb-26-21 | Downgrade | Colliers Securities | Buy → Neutral |
Jan-29-21 | Reiterated | Needham | Hold |
Nov-17-20 | Downgrade | Oppenheimer | Outperform → Perform |
Sep-11-20 | Initiated | Needham | Hold |
Sep-02-20 | Initiated | Robert W. Baird | Neutral |
Aug-07-20 | Upgrade | Colliers Securities | Neutral → Buy |
Aug-05-20 | Upgrade | Oppenheimer | Perform → Outperform |
Mar-05-20 | Initiated | Citigroup | Buy |
Feb-06-20 | Initiated | BTIG Research | Buy |
Jan-10-20 | Initiated | William Blair | Outperform |
Jan-08-20 | Initiated | SunTrust | Buy |
Oct-22-19 | Initiated | Oppenheimer | Perform |
Feb-20-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
Sep-13-18 | Reiterated | Canaccord Genuity | Buy |
Sep-06-18 | Initiated | Chardan Capital Markets | Buy |
Aug-02-18 | Upgrade | Dougherty & Company | Sell → Neutral |
Jul-16-18 | Downgrade | Dougherty & Company | Neutral → Sell |
Dec-01-17 | Initiated | Dougherty & Company | Neutral |
View All
Irhythm Technologies Inc Stock (IRTC) Latest News
Director Abhijit Talwalkar Acquires 6,664 Shares of iRhythm Tech - GuruFocus.com
iRhythm Technologies, Inc. (NASDAQ:IRTC) CEO Sells $1,249,784.45 in Stock - MarketBeat
iRhythm Technologies, Inc. (NASDAQ:IRTC) Director Acquires $500,866.24 in Stock - MarketBeat
iRhythm Technologies (NASDAQ:IRTC) Stock Price Up 7.8%What's Next? - MarketBeat
iRhythm Technologies Inc (IRTC) Trading 4.41% Higher on Nov 4 - GuruFocus.com
iRhythm Technologies, Inc. (NASDAQ:IRTC) Shares Purchased by Harbor Capital Advisors Inc. - MarketBeat
Emerging Opportunities in the Ecg Sensor Patch Market - openPR
Q1 EPS Forecast for iRhythm Technologies Raised by Analyst - MarketBeat
Trend Tracker for (IRTC) - Stock Traders Daily
IRHYTHM ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Earnings call: iRhythm Reports Growth Amid FDA Remediation Efforts By Investing.com - Investing.com Australia
iRhythm Leaders Concealed Heart Monitor Deficiencies, Suit Says - Bloomberg Law
FDA clears iRhythm’s second 510(k) in response to warning letter - MedTech Dive
iRhythm Technologies Third Quarter 2024 Earnings: EPS Misses Expectations - Simply Wall St
Here’s Why iRhythm Technologies (IRTC) Slid in Q3 - Insider Monkey
iRhythm Technologies, Inc. (NASDAQ:IRTC) Just Reported, And Analysts Assigned A US$101 Price Target - Yahoo Canada Finance
iRhythm Technologies (NASDAQ:IRTC) Price Target Lowered to $79.00 at Robert W. Baird - MarketBeat
iRhythm Technologies, Inc. (NASDAQ:IRTC) Q3 2024 Earnings Call Transcript - Insider Monkey
Stephens Investment Management Group LLC Has $29.72 Million Stock Position in iRhythm Technologies, Inc. (NASDAQ:IRTC) - MarketBeat
iRhythm stock holds Buy as Needham adjusts target, highlights strong Zio AT momentum - Investing.com Australia
Why iRhythm Technologies Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - MSN
Earnings call: iRhythm Reports Growth Amid FDA Remediation Efforts - Investing.com
Forecasting The Future: 6 Analyst Projections For iRhythm Technologies - Benzinga
iRhythm Technologies (NASDAQ:IRTC) Posts Quarterly Earnings Results, Misses Estimates By $0.71 EPS - MarketBeat
iRhythm Technologies Gains FDA Clearance for Zio Design Changes - MPO-mag
iRhythm Technologies (NASDAQ:IRTC) Shares Gap Down on Disappointing Earnings - MarketBeat
FDA clears second set of changes to iRhythm Zio AT to resolve warning letter - Mass Device
Needham & Company LLC Cuts iRhythm Technologies (NASDAQ:IRTC) Price Target to $96.00 - MarketBeat
IRhythm Technologies (IRTC) Reports Q3 Loss, Tops Revenue Estimates - MSN
iRhythm Technologies, Inc. (NASDAQ:IRTC) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
iRhythm Technologies Inc (IRTC) Q3 2024 Earnings Call Highlights: Strong Revenue Growth Amid ... - Yahoo Finance
FDA clears iRhythm's Zio AT device enhancements for 2025 By Investing.com - Investing.com Canada
FDA clears iRhythm's Zio AT device enhancements for 2025 - Investing.com India
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device - The Manila Times
iRhythm Technologies Announces Third Quarter 2024 Financial Results - The Manila Times
Earnings Preview For iRhythm Technologies - Benzinga
Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy - The Manila Times
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio? - Benzinga
iRhythm shares soar after FDA clears Zio AT device updates - MSN
IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc.IRTC - Business Wire
iRhythm’s Zio AT design changes win FDA clearance - MedTech Dive
iRhythm Technologies (IRTC) Soars 21.7%: Is Further Upside Left in the Stock? - MSN
iRhythm Technologies (IRTC) to Release Quarterly Earnings on Wednesday - MarketBeat
BTIG bullish on iRhythm stock, FDA clearance partially lifts regulatory overhang - Investing.com Canada
iRhythm Technologies, Inc. (NASDAQ:IRTC) Stock Position Raised by Allspring Global Investments Holdings LLC - MarketBeat
Truist raises iRhythm stock target, keeps at Buy list on FDA approval By Investing.com - Investing.com South Africa
Truist raises iRhythm stock target, keeps at Buy list on FDA approval - Investing.com Nigeria
iRhythm Technologies: Today's 510(K) Victory May Only Be A Temporary Reprieve - Seeking Alpha
IRhythm Earns FDA Nod For Zio AT After Warning Letter - MPO-mag
How to Take Advantage of moves in (IRTC) - Stock Traders Daily
iRhythm Technologies (NASDAQ:IRTC) Price Target Raised to $95.00 - MarketBeat
Irhythm Technologies Inc Stock (IRTC) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):